Expert Review of Neurotherapeutics最新文献_第7页

Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine. Rimegepant 和 atogepant：为偏头痛治疗提供创新机会的新型药物。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-12 DOI: 10.1080/14737175.2024.2401558

William David Wells-Gatnik,Lanfranco Pellesi,Paolo Martelletti

{"title":"Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine.","authors":"William David Wells-Gatnik,Lanfranco Pellesi,Paolo Martelletti","doi":"10.1080/14737175.2024.2401558","DOIUrl":"https://doi.org/10.1080/14737175.2024.2401558","url":null,"abstract":"INTRODUCTIONRimegepant and atogepant, two innovative oral medications for the treatment of migraine, are gaining prominence in the treatment of migraine. However, outside of specialist headache centers, these novel medications remain subjectively underutilized. While multiple rationales exist describing their underutilization, a leading factor is the complexity and clinical flexibility attributed to the individual members of the gepant medication class.AREAS COVEREDThis review provides a brief review of the current uses, common adverse events, and potential areas of future clinical innovation attributed to rimegepant and atogepant. A database search for the term 'Rimegepant OR Atogepant' was completed, yielding 240 individual results. Following multiple rounds of assessment that aimed to determine relevance of each individual result, 42 studies were included in the synthesis of this review.EXPERT OPINIONRimegepant and atogepant are exciting medications that demonstrate significant clinical innovation within the field of migraine therapy. While current indications are clear, data is lacking regarding the future expanded roles of these medications. Current areas of potential therapeutic innovation for rimegepant and atogepant include the pediatric population, in pregnancy and breastfeeding, in cluster headache and post-traumatic headache, and in patients that previously discontinued calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) therapy.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":"6 1","pages":"1-11"},"PeriodicalIF":4.3,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142205617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sacroiliac joint pain: what treatment and when. 骶髂关节疼痛：何时治疗？

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-11 DOI: 10.1080/14737175.2024.2400682

Federico Cocconi,Nicola Maffulli,Andreas Bell,Michael Kurt Memminger,Francesco Simeone,Filippo Migliorini

{"title":"Sacroiliac joint pain: what treatment and when.","authors":"Federico Cocconi,Nicola Maffulli,Andreas Bell,Michael Kurt Memminger,Francesco Simeone,Filippo Migliorini","doi":"10.1080/14737175.2024.2400682","DOIUrl":"https://doi.org/10.1080/14737175.2024.2400682","url":null,"abstract":"INTRODUCTIONSpinal and non-spinal pathologies can cause low back pain. Non-spinal sources of low back pain include the sacroiliac joint (SIJ) and the hip. SIJ pain can be treated either conservatively or surgically. Current strategies for managing sacroiliac joint pain are debated, and limited evidence exists.AREAS COVEREDThe present expert opinion updates current evidence on conservative and surgical modalities for SIJ pain.EXPERT OPINIONSurgical management for SIJ pain is effective. However, it exposes patients to surgery and, therefore, related complications. Conservative management may be implemented in patients with moderate SIJ pain, with less than six months of symptoms, or not eligible for surgery. Several noninvasive modalities are available, mostly centered on intra-articular injections. Corticosteroids, platelet-rich plasma, and stem cells have only midterm lasting effects, at most for nine months. Radiofrequency ablation is another methodology for pain relief. Both continuous and pulsatile radiofrequency ablation are associated with good outcomes. SIJ fusion can be performed using different techniques; however, a clear recommendation on the most appropriate modality for the management of SIJ pain is still debated.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":"15 1","pages":"1-8"},"PeriodicalIF":4.3,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142205598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When is pharmacological intervention recommended for adults with social anxiety disorder? 何时建议对患有社交焦虑症的成年人进行药物干预？

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-10 DOI: 10.1080/14737175.2024.2401556

Franklin R Schneier

引用次数: 0

Correction. 更正。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-08 DOI: 10.1080/14737175.2024.2398883

引用次数: 0

Advances in the medical treatment and diagnosis of intracranial hemorrhage associated with oral anticoagulation. 与口服抗凝药有关的颅内出血的医疗和诊断进展。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-01 Epub Date: 2024-07-22 DOI: 10.1080/14737175.2024.2379413

Claudio Piqueras-Sanchez, María Asunción Esteve-Pastor, Jorge Moreno-Fernandez, Eva Soler-Espejo, José Miguel Rivera-Caravaca, Vanessa Roldán, Francisco Marín

{"title":"Advances in the medical treatment and diagnosis of intracranial hemorrhage associated with oral anticoagulation.","authors":"Claudio Piqueras-Sanchez, María Asunción Esteve-Pastor, Jorge Moreno-Fernandez, Eva Soler-Espejo, José Miguel Rivera-Caravaca, Vanessa Roldán, Francisco Marín","doi":"10.1080/14737175.2024.2379413","DOIUrl":"10.1080/14737175.2024.2379413","url":null,"abstract":"Introduction: With the increasing prevalence of atrial fibrillation (AF), it entails expanding oral anticoagulants (OACs) use, carrying a higher risk of associated hemorrhagic events, including intracranial hemorrhage (ICH). Despite advances in OACs development with a better safety profile and reversal agent for these anticoagulants, there is still no consensus on the optimal management of patients with OACs-associated ICH.Areas covered: In this review, the authors have carried out an exhaustive search on the advances in recent years. The authors provide an update on the management of ICH in anticoagulated patients, as well as an update on the latest evidence on anticoagulation resumption, recent therapeutic strategies, and investigational drugs that could play a role in the future.Expert opinion: Following an ICH event in an anticoagulated patient, a comprehensive clinical evaluation is imperative. Anticoagulation should be promptly withdrawn and reversed. Once the patient is stabilized, a reintroduction of anticoagulation should be considered, typically within a timeframe of 4-8 weeks, if feasible. If re-anticoagulation is not possible, alternative options such as Left Atrial Appendage Occlusion are available.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"913-928"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gantenerumab for early Alzheimer's disease: a systematic review and meta-analysis. 甘特宁单抗治疗早期阿尔茨海默病：系统综述和荟萃分析。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-01 Epub Date: 2024-06-16 DOI: 10.1080/14737175.2024.2367016

Artur Menegaz de Almeida, Marianna Leite, Lucca Moreira Lopes, Pedro Gomes Lima, Maria Luísa Siegloch Barros, Samuel Rocha Pinheiro, Ítalo Andrade, Patrícia Viana, Victória Morbach, Gabriel Marinheiro, Ricardo de Oliveira, Agostinho C Pinheiro

{"title":"Gantenerumab for early Alzheimer's disease: a systematic review and meta-analysis.","authors":"Artur Menegaz de Almeida, Marianna Leite, Lucca Moreira Lopes, Pedro Gomes Lima, Maria Luísa Siegloch Barros, Samuel Rocha Pinheiro, Ítalo Andrade, Patrícia Viana, Victória Morbach, Gabriel Marinheiro, Ricardo de Oliveira, Agostinho C Pinheiro","doi":"10.1080/14737175.2024.2367016","DOIUrl":"10.1080/14737175.2024.2367016","url":null,"abstract":"Introduction: Gantenerumab is a monoclonal antibody targeting amyloid β protein (Aβ) in early Alzheimer's disease (AD). The authors sought to evaluate gantenerumab safety and efficacy in early AD patients.Methods: MEDLINE, Embase, and Cochrane databases were systematically searched until 2 December 2023. Data were examined using the Mantel-Haenszel method and 95% confidence intervals (CIs). Meta-regression analysis was conducted to evaluate a possible link between baseline Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) and amyloid-related imaging abnormalities (ARIA) at follow-up. R, version 4.2.3, was used for statistical analysis.Results: A total of 4 RCTs and 2848 patients were included, of whom 1580 (55%) received subcutaneous gantenerumab. Concerning clinical scores, the placebo group achieved better rates of change in the Disease Assessment Scale (ADAS-Cog13) (SMD -0.11; 95% CI -0.19- -0.03; p = 0.008569; I2 = 0%). Gantenerumab was strongly associated with the occurrence of ARIA-E and ARIA-H: (19.67% vs. 2.31%; RR 9.46; 95% CI 5.55-16.11; p = <0.000001; I2 = 10%) and (21.95% vs. 12.38%; RR 1.79; 95% CI 1.50-2.13; p = <0.000001; I2 = 0%), respectively.Discussion: In this meta-analysis, consistent results suggest that gantenerumab is not safe and efficient for early AD, showing no improvement in clinical scores for AD and being associated with the occurrence of ARIA-E and ARIA-H.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"929-936"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141327373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Profiling the combination of bupropion and dextromethorphan as a treatment option for major depressive disorder. 分析安非他酮和右美沙芬的组合作为治疗重度抑郁障碍的一种选择。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-01 Epub Date: 2024-07-22 DOI: 10.1080/14737175.2024.2374024

Joseph Blanco, Pamela Quimbaya, Manuel Mena, Seetal Dodd, Rosa-Helena Bustos

{"title":"Profiling the combination of bupropion and dextromethorphan as a treatment option for major depressive disorder.","authors":"Joseph Blanco, Pamela Quimbaya, Manuel Mena, Seetal Dodd, Rosa-Helena Bustos","doi":"10.1080/14737175.2024.2374024","DOIUrl":"10.1080/14737175.2024.2374024","url":null,"abstract":"Introduction: Major Depressive Disorder (MDD) is a common mental health disorder marked by sadness, hopelessness, and anhedonia. Various therapies exist, but their effectiveness is limited. Dextromethorphan hydrobromide combined with bupropion hydrochloride (Auvelity®) is a recently approved alternative for treating this condition in adults.Areas covered: This review summarizes the neurobiology of major depression and delves into the pharmacology, efficacy, safety, and tolerability of dextromethorphan plus bupropion in adult patients. It is based on observational studies, clinical trials, and other secondary studies obtained through systematic literature searches.Expert opinion: The combination of bupropion and dextromethorphan as a new pharmacotherapy for mental health is an interesting addition to the treatment options that can be used for MDD. The combination can be used in a range of scenarios, including as a first line therapy, as a second option when a patient has failed to achieve remission with a serotonin targeting agent, and for treatment resistant depression. Further research for other indications, including addiction disorders, may provide exciting results. Although a new combination, clinicians will be very familiar with both agents, increasing their acceptability. This pharmacotherapy also may bring increased impetus for discovering other combinations that may have beneficial synergistic effects.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"837-848"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Re-evaluating the prognosis of schizophrenia: tackling the issue of inadequate treatment. 重新评估精神分裂症的预后：解决治疗不当的问题。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-01 Epub Date: 2024-06-16 DOI: 10.1080/14737175.2024.2365943

Ofer Agid

引用次数: 0

Risk of suicide and suicide-related events in subjects treated with antiseizure medications. 接受抗癫痫药物治疗的受试者自杀和自杀相关事件的风险。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-01 Epub Date: 2024-07-08 DOI: 10.1080/14737175.2024.2376110

Boulenouar Mesraoua, Francesco Brigo, Bassel Abou-Khalil, Musab Ali, Simona Lattanzi

{"title":"Risk of suicide and suicide-related events in subjects treated with antiseizure medications.","authors":"Boulenouar Mesraoua, Francesco Brigo, Bassel Abou-Khalil, Musab Ali, Simona Lattanzi","doi":"10.1080/14737175.2024.2376110","DOIUrl":"10.1080/14737175.2024.2376110","url":null,"abstract":"Introduction: In the United States, it is reported that 1.4% of the general population commits suicide. It has been postulated that antiseizure medications (ASMs) can lead to the development of suicidal ideation and suicidal behavior; however, this risk is still very low and has yet to be precisely established.Areas covered: This narrative review evaluates the risk of suicide-related events (SREs) in subjects taking ASMs for various neurological disorders. Screening tools for suicidal ideation and suicidal behavior are also discussed. References for this article were found using PubMed/MEDLINE.Expert opinion: Although some ASMs can be associated with SREs, this is not yet clearly established. The mechanisms involved in suicide risk in subjects taking ASMs are multifactorial. The bidirectional relationship between depression and epilepsy, as well as other associations, should be kept in mind when interpreting any impact of ASMs in PWE. Screening for SREs, close monitoring of subjects taking ASMs are the most appropriate strategies to minimize suicide risk. More efforts should be made to achieve accurate risk stratification through prognostic models that could be applied to subjects taking ASMs. Studies exploring the association between ASMs and suicide should consider ASMs individually and control for prior SREs.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"865-878"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Are ketamine and its enantiomers the answer to treatment-refractory depression? 氯胺酮及其对映体是治疗难治性抑郁症的答案吗？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-01 Epub Date: 2024-06-27 DOI: 10.1080/14737175.2024.2373302

Jean-Baptiste Belge, Gabrielle Scantamburlo, Eric Constant

引用次数: 0